Aikang Pharma focuses its primary operations on Phase I-IV clinical trials and Bioequivalence (BE) studies, specializing in drug clinical research CRO services and comprehensive support for IND, ANDA, and NDA registrations. Our commitment lies in delivering pharmaceutical companies specialized services in drug clinical CRO and regulatory submissions for the Chinese market, expediting the process of product market entry.

Our core team excels in clinical research, particularly in the fields of psychiatry, respiratory medicine, anesthesia, infection, and gastroenterology. We bring significant expertise to challenging areas such as sustained-release injectables, endogenous substances, inhalation formulations, and highly variable drugs. Leveraging the solid pharmaceutical research foundation of Chiheal Biomed, we collaborate with renowned domestic experts in clinical, statistical, and analytical fields to provide end-to-end, specialized CRO, and R&D management services for pharmaceutical production enterprises and research institutions. Our vision is to become a leader in China's pharmaceutical R&D service sector.